This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biomarin Pharmaceutical Inc (BMRN)

NASDAQ: Health Care

Company Income Statement
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Sales 751.04M 548.48M 500.72M 441.36M
Cost of Sales 83.78M 61.31M 60.78M 45.32M
Gross Operating Profit 667.26M 487.17M 439.94M 396.04M
Selling, General, and Administrative Expenses 302.16M 235.36M 198.17M 175.42M
Research & Development 461.54M 354.78M 302.22M 214.37M
Operating Income before D & A (EBITDA) -96.44M -102.96M -60.45M 6.24M
Depreciation & Amortization 63.96M 53.04M 49.76M 40.13M
Interest Income 5.94M 3.08M 2.58M 2.93M
Other Income - Net 67.10M -11.98M -1.79M -1.90M
Special Income / Charges 0.00 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) -88.23M -166.06M -110.64M -35.28M
Interest Expense 36.64M 10.45M 7.64M 8.35M
Pre-Tax Income -124.87M -176.50M -118.28M -43.63M
Income Taxes 9.10M -150.00K -3.93M 10.21M
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations -133.97M -176.35M -114.35M -53.84M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations -133.97M -176.35M -114.35M -53.84M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income -133.97M -176.35M -114.35M -53.84M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-133.97M -176.35M -114.35M -53.84M
Preferred Dividends
Net Income Available To Common -133.97M -176.35M -114.35M -53.84M
Basic EPS from Continuing Ops. -0.92 -1.28 -0.95 -0.48
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations -0.92 -1.28 -0.95 -0.48
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total -0.92 -1.28 -0.95 -0.48
Basic Normalized Net Income/Share -0.92 -1.28 -0.95 -0.48
EPS fr Continuing Ops. -0.92 -1.28 -0.95 -0.48
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. -0.92 -1.28 -0.95 -0.48
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total -0.92 -1.28 -0.95 -0.48
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-0.92 -1.28 -0.95 -0.48
Dividends Paid per Share 0.00 0.00 0.00 0.00
BMRN News

BMRN Biomarin Pharmaceutical Inc

Chart of BMRN

Analysts Ratings for BMRN

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 10 10 11 11
Moderate Buy 1 1 1 1
Hold 3 3 3 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET BMRN ANALYST REPORT

Brokerage Partners

BMRN Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs